Jan 5, 2009 by Brian Orelli, PhDPfizer Goes Shopping and Water Is Wet: News at 11!Stop worrying about what the company might buy.
Dec 31, 2008 by Brian Orelli, PhDHealth Care's Golden ChildrenThe whole industry wasn't down this year.
Dec 31, 2008 by Brian Orelli, PhDMedical Device Makers Are as Cheap as EverValue investing, health-care style.
Dec 31, 2008 by Brian Orelli, PhDBayer's Little Lost Drug PatentThe drugmaker is dusting one off and suing Abbott Labs.
Dec 31, 2008 by Brian Orelli, PhDAn Imminent Drug Approval? Really?Lilly may finally hear about prasugrel.
Dec 30, 2008 by Brian Orelli, PhDThe FDA Needs a Bake SaleThe agency needs a fundraiser more than anything.
Dec 30, 2008 by Brian Orelli, PhDA Shot in the Arm for Novartis' PipelineThe company picks up the rights to a vaccine that fights a virus.
Dec 30, 2008 by Brian Orelli, PhDA Post-Holiday Breakup ... of SortsAbbott and Celera revise their partnership.
Dec 30, 2008 by Brian Orelli, PhD2009's Generic Drugs: Who's at RiskThe patent cliff is coming early for some drugmakers.
Dec 19, 2008 by Brian Orelli, PhDEli Lilly's Good News Misses the MarkEU approval of its blood thinner is nice, but U.S. approval is what will really matter.
Dec 19, 2008 by Brian Orelli, PhDOpen-Label Bites Drug DuoPfizer and Celldex have to make the best of a bad situation.
Dec 18, 2008 by Brian Orelli, PhDA Peek Inside Aetna's BooksThe health insurer has achieved a happy medium.
Dec 18, 2008 by Brian Orelli, PhDA Diagnostic Tongue TwisterBack-scratch fever between Abbott and Isis.
Dec 17, 2008 by Brian Orelli, PhDA Super-Cheap Call OptionGlaxo's pay-if-the-drug-works scheme should pay off.
Dec 16, 2008 by Brian Orelli, PhDPfizer Keeps the ChangeFor the first time in decades, investors won't get a dividend increase.
Dec 16, 2008 by Brian Orelli, PhDDoubling Up on Triple Lipid DrugsLike a double cheeseburger, only healthier.
Dec 15, 2008 by Brian Orelli, PhDA Potentially Game-Changing MS DrugThe newest data looks good, but longer studies are the key for Novartis.
